Department of Cardiovascular Surgery,Shimane Prefectural Central Hospital

• Published in: Medical Journal of Shimane Prefectural Central Hospital Vol. 47; no. 1; pp. 11 - 16
• Main Author: Yamauchi, Masanobu
• Format: Journal Article
• Language: Japanese
• Published: Shimane Prefectural Central Hospital 10.03.2023; 島根県立中央病院
• Subjects: Mitroflow, aortic valve replacement, structural valve deterioration, reoperation; Mitroflow弁，大動脈弁置換術，人工弁機能不全，再手術
• ISSN: 0289-5455; 2435-0710
• DOI: 10.34345/spch.47.1_11

The use of bioprosthetic valves in aortic valve replacement surgery is increasing due to the aging of patients, dietary restrictions associated with anticoagulation therapy, and avoidance of bleeding risks. However, some reports have raised concerns about the durability of the Mitroflow valve, and we investigated the remote results of the Mitroflow valve in our department. The subjects were 15 patients who underwent aortic valve eplacement using the Mitroflow valve from December 2013 to August 2022. The mean age was 77.5±5.6 years, all were female, the mean body surface area was 1.3±0.1m2, and all valve sizes were 19mm. One patient was lost to mediastinitis in the early postoperative period, but the others were discharged from the hospital without any complications. One patient underwent aortic valve replacement due to structural valve deterioration at 2.7 years postoperatively. Another patient had rapidly progressive stenosis of the Mitroflow valve（SVD）at 5.6 years postoperatively. There were 3 remote deaths（heart failure at 7.5 years postoperatively, acute myocardial infarction at 4 years postoperatively, and senility at 3.8years postoperatively）. By the Kaplan-Meier method, the cardiac associated mortality free rates were 100% at 1 and 3 years, 88% at 5 and 7 years, and the all-cause mortality free rates were 93% at 1 and 3 years, and 72% at 5 and 7 years. Reoperation and SVD free rates were 100% at 1 year, 90% at 3 and 5 years, and 77% at 7 years. Two of 15 patients with 19mm Mitroflow valves in our department had early SVD, suggesting the need for stricter indication and postoperative follow-up for Mitroflow valves.